scholarly journals When to start tacrolimus ointment for vernal keratoconjunctivitis? A proposed treatment protocol

2022 ◽  
Author(s):  
Roee Arnon ◽  
Irit Rozen-Knisbacher ◽  
Tal Yahalomi ◽  
Nir Stanescu ◽  
Yulia Niazov ◽  
...  
Keyword(s):  
Treatment Protocol ◽  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment

scholarly journals When To Start Tacrolimus Ointment For Vernal Keratoconjunctivitis? A Proposed Treatment Protocol

2021 ◽  
Author(s):  
Roee Arnon ◽  
Irit Rozen - Knisbacher ◽  
Tal Yahalomi ◽  
Nir Stanescu ◽  
Yulia Niazov ◽  
...  
Keyword(s):  
Clinical Signs ◽  
Treatment Protocol ◽  
Topical Steroid ◽  
Case Series ◽  
Topical Steroids ◽  
Line Treatment ◽  
Tacrolimus Ointment ◽  
Disease Remission ◽  
The Mean ◽  
Topical Treatments

Abstract PurposeThe aim of this study was to compare treatment regimens of tacrolimus and of topical steroids for VKC and suggest a treatment protocol according to our clinical experience.MethodsThis retrospective, nonrandomized case series enrolled 85 Patients with VKC. Patients were classified clinically according to severity (mild, moderate, severe) and were treated according to a suggested protocol. Analysis was made according to treatment received: tacrolimus ointment as first line treatment (tacrolimus 1st line), tacrolimus ointment after topical steroid drops treatment (tacrolimus 2nd line) and topical steroid drops or artificial tears alone (topical steroid and tears group). Results Significant improvements in clinical signs and symptoms were achieved under tacrolimus treatment 14 months in the moderate group and 5 months in the severe group. The longest duration of treatment was for tacrolimus 2nd line group (p=0.031) and the mean number of visits in the clinic was the highest. The mean number of topical treatments per day was higher in the topical steroid and tears group (2.6 times) than in the two tacrolimus groups (1.3 times for both). The mean time needed to achieve disease remission or relief did not differ between the tacrolimus 1st line and 2nd line groups.ConclusionTacrolimus treatment is effective and safe for VKC. Tacrolimus as 1st line treatment may be preferred for severe cases, for faster disease remission compared to tacrolimus as 2nd line treatment; and with fewer topical treatments per day compared to topical steroids.

scholarly journals The Efficacy of 0.03% Dermatological Tacrolimus Ointment for Refractory Vernal Keratoconjunctivitis.

2020 ◽  
Vol 35 (4) ◽  
pp. 229-234
Author(s):  
Hafiza Sadia Imtiaz
Keyword(s):  
Clinical Symptoms ◽  
Clinical Signs ◽  
Vernal Keratoconjunctivitis ◽  
P Value ◽  
Baseline Score ◽  
Assessment Data ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Quasi Experimental ◽  
Written Informed Consent

  Purpose: To determine the efficacy of 0.03% dermatological tacrolimus ointment in patients with refractory vernal keratoconjunctivitis Study Design: Quasi-experimental study Study Place and Duration: Eye Department, DHQ-Teaching Hospital, Gujranwala, Pakistan from April 2018 to March 2019 Material and Methods: After approval from hospital ethical committee and obtaining written informed consent from each patient/guardian, patients of either gender between 4-16 years of age with VKC not responding to conventional treatment for more than 8 weeks or having steroid-induced complications were included in this study. Dermatological tacrolimus ointment 0.03% started to be placed in inferior fornix in BD frequency along with topical lubricants. Patients were followed up on a regular schedule. Individual symptoms score was assessed from the questionnaire and signs score from observer’s clinical assessment. Data were analyzed using SPSS v23.0. P-value <0.05 was considered as statistically significant. Results: 40 eyes of 20 patients were included in this study. Out of which 4(20%) were female and 16 were male (80%). Mean baseline score for clinical symptoms was 6.65±1.81 that reduced to 1.65±0.81 after 12 weeks treatment course of tacrolimus with a significant p-value of 0.006 (p<0.05). Mean baseline score for clinical signs was 5.9±1.59 that improved to 1.80±0.83 after 12 weeks treatment course with a statistically significant p-value of 0.003 (p<0.05). Conclusions: In conclusion, topical tacrolimus dermatological ointment 0.03% is highly effective in refractory VKC and can be safely used as an alternative in VKC patients who are steroid-responders.

scholarly journals Tacrolimus ointment for treatment of vernal keratoconjunctivitis

2016 ◽  
Vol 23 (1) ◽  
pp. 135 ◽  
Author(s):  
AbdulrahmanM Al-Amri ◽  
AleemGulzar Mirza ◽  
AhmedMossa Al-Hakami
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment

scholarly journals Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis

2019 ◽  
Vol 82 (2) ◽  
Author(s):  
Guilherme Gubert Müller ◽  
Newton Kara José ◽  
Rosane Silvestre de Castro ◽  
Erick Carneiro de Holanda
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Effective Option

scholarly journals Tacrolimus Ointment for Treatment of Vernal keratoconjunctivitis

2017 ◽  
Vol 16 (03) ◽  
pp. 29-37
Author(s):  
Dr. Jitendra kumar ◽  
Dr. Shweta dwivedi ◽  
Dr.Amit Verma ◽  
Dr.Arun Kumar pathak
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment

Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis

2019 ◽  
Vol 257 (5) ◽  
pp. 967-974 ◽  
Author(s):  
Fang-Yu Liu ◽  
Hsin-Yu Liu ◽  
Hsiao-Sang Chu ◽  
Wei-Li Chen ◽  
Fung-Rong Hu ◽  
...  
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment ◽  
Steroid Refractory

scholarly journals Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives

2021 ◽  
Vol 14 (7) ◽  
pp. 658
Author(s):  
DeGaulle I. Chigbu ◽  
Bisant A. Labib
Keyword(s):  
Daily Living ◽  
Drug Targets ◽  
Allergic Conjunctivitis ◽  
Vision Loss ◽  
Treatment Protocol ◽  
Vernal Keratoconjunctivitis ◽  
Future Perspectives ◽  
Th2 Cell ◽  
Standardized Treatment ◽  
Potential Drug Targets

Vernal keratoconjunctivitis (VKC) is a complex and chronic, multifactorial Th2 cell-mediated chronic ocular surface inflammatory condition that typically affects predominantly male children in hot or warm climates. The primary symptom is intense ocular pruritus, often significant enough to affect activities of daily living. Clinical features differ from simple forms of allergic conjunctivitis in that they are more-or-less confined to the superior tarsus and limbus. There is also a risk of corneal involvement, which leads to irreversible vision loss in approximately 6% of patients. Right now, there is no standardized treatment protocol, and many of the currently available options are not effective in severe and recurrent cases. As such, it is imperative to understand this complex allergic immune response in order to identify future therapeutic targets. This review will focus on potential drug targets in VKC, with particular emphasis on immunomodulators and immunobiologic agents.

Sign in / Sign up

Export Citation Format

Share Document